Corrected: BRIEF-AbbVie Inc outlook FY adjusted EPS USD 13.87 - 14.07
31/07/2026 12:48
CORRECTED-BRIEF-AbbVie Inc outlook FY adjusted EPS USD 13.87 - 14.07 Jul 31 (Reuters) - AbbVie Inc Q2 Global Skyrizi revenue USD 5,505 million.
- Q2 Global Rinvoq revenue USD 2,525 million
- Q2 EPS USD 2.03
- Q2 revenue USD 16,990 million vs. IBES estimate USD 16,765 million
- Q2 Global Humira revenue USD 756 million
- Q2 Adjusted EPS USD 3.65 Vs. IBES Estimate USD 3.6
- Q2 RESULTS INCLUDE AN UNFAVORABLE IMPACT OF $0.17/SHARE RELATED TO ACQUIRED IPR&D AND MILESTONES EXPENSE
- FY 2026 ADJ EPS GUIDANCE INCLUDES $0.14 /SHARE DILUTIVE IMPACT RELATED TO ACQUISITION OF APOGEE THERAPEUTICS
Recent news on AbbVie
See all newsBrief: Abbvie Reaches Agreement With The Pan-Canadian Pharmaceutical Alliance (Pcpa) For Elahere® In Platinum-Resistant Ovarian Cancer
Eli Lilly hits record high as healthcare stocks rally
Nvidia-backed Iambic Therapeutics tumbles below IPO price
Factbox: Pharma sector doubles down on AI to slash costs, timelines
Brief: Abbvie Says Risankizumab In Ulcerative Colitis Shows Clinical Remission Rates Of 54.0%-73.1% At Week 96